- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01052090
Safety and Efficacy Study in Hepatitis C Patients With PHN121 (ENCHAMP)
Safety and Efficacy Study in Non-Responder Hepatitis C Genotype 1 Patients With PHN121
Study Overview
Detailed Description
This is a Phase I/II, open-label, multicenter (2 centers), dose-escalation, multidose study in non-responder hepatitis C genotype 1 patients. Three escalating dose levels will be evaluated. Each cohort of 6 subjects will enroll sequentially. Each cohort will be administered PHN121 orally daily for 12 weeks. Subjects will be requested to return on Week 2, Week 4, Week 6, and Week 9 for evaluation and medication. Subjects will also be asked to return for follow-up evaluation for adverse events on Week 12 and Week 16.
Three doses are planned and include: 2.91, 4.85, and 7.77 g/day. Subjects will be assigned to a dose level in the order of study entry. Initially, 6 subjects will be enrolled at each dose level; up to 8 subjects may be assigned to each dose level, depending upon dose-limiting toxicities (DLTs) seen.
Six subjects will be started on treatment with dose level 1. After the sixth subject completes 84 days of treatment, if no dose-limiting toxicity occurs, then the next group of 6 subjects will be treated at the next higher dose regimen. If 1 of the 6 initial subjects experiences a DLT, the cohort of subjects will be expanded to 8 subjects. If fewer than two DLTs occur in 8 subjects, then the next higher dose group will be initiated. If 2 of the 6 initial subjects or 3 or more (of a cohort of up to 8) subjects experience DLTs, no further dose escalations will occur; the study will be discontinued and the MTD will have been exceeded.
No subject may participate in more than 1 cohort.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Kaohsiung, Taiwan
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
Taipei, Taiwan
- PhytoHealth
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Nonsmoking adult subjects age 20 years or above, male or female
- Non-Responder HCV patient who failed to achieve sustained viral response (SVR), either do not respond or relapse, to prior 24-week interferon based therapy
- Any antiviral agent discontinued at least 4 weeks before the screening visit.
- Presence of anti-HCV in serum
- Serum and PCR positive for HCV-RNA*1 (Genotype 1)
- Elevated ALT (> 1.3 x upper limit of normal) during last 6 months and (1.3 x to 10 x upper limit of normal) during the screening phase
- No evidence showing liver cirrhosis or hepatocellular carcinoma*2
Hematological, biochemical and serologic criteria at the screening phase is within normal limits (WNL):
- Hemoglobin values of > 12gm/dl for females and > 13gm/dl for males
- WBC > 3,000/mm3
- Neutrophil > 1,500/mm3
- Platelets count > 90,000/mm3
- Normal PT (INR< 1.2)
- Total bilirubin < 2 mg/dl
- Albumin, WNL
- Serum creatinine, WNL
- Written informed consent
Exclusion Criteria:
- Has evidence of significant renal, cardiovascular, hematopoetic, neurological, pulmonary or gastrointestinal pathology, or any other medical reason or disease that might interfere with the study objectives, as determined by the investigator
- Has participated in other investigational trials within 28 days prior to study enrollment
- Has taken botanical medications*3 within 28 days prior to study enrollment
- Has an surgery within 28 days prior to study enrollment
Has been diagnosed with any other cause for the liver disease other than chronic hepatitis C including the following conditions:
- Co-infection with HBV
- Hemochromatosis
- Alpha-1 antitrypsin deficiency
- Wilson's disease
- Autoimmune hepatitis
- Alcoholic liver disease
- Drug-related liver disease
- Other liver disease that was considered by the principal investigator
- Has been test positive for HIV
- Has been diagnosed with poor-controlled Diabetes Mellitus (HbA1C > 9.0%)
- Active alcohol abuse of daily intake > 30 g for male and > 20 g for female within the previous 1 year
- Active substance abuse, such as inhaled or injection drugs within the previous 1 year *4
- Female subjects of child bearing potential who are pregnant, nursing, do not agree to practice effective birth control during the time period from 14 days before administration of study drug to 28 days after administration of study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lifestyle counseling
|
a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety: Safety assessments will include ALT, aspartate aminotransferase (AST), other clinical laboratory tests, HCV RNA quantitation, vital signs, physical examinations, concomitant medications, and adverse events (AEs).
Time Frame: 12-week treatment; 4-week safety followup
|
12-week treatment; 4-week safety followup
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy: Efficacy will be assessed by evaluating the plasma concentrations of ALT and viral load through calculating the percent change from Baseline on a per-subject and by-cohort basis, normalizing to the baseline measurement.
Time Frame: 12-week treatment; 4-week safety followup
|
12-week treatment; 4-week safety followup
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Wan-Long Chuang, M.D., Ph.D., Kaohsiung Municipal United Hospital
- Principal Investigator: Ming-Lung Yu, M.D., Ph.D., Kaohsiung Municipal United Hospital
- Principal Investigator: Chia-Yen Dai, M.D., M.S., Kaohsiung Municipal United Hospital
Publications and helpful links
General Publications
- Dai CY, Chuang WL, Huang JF, Hsieh MY, Yu ML. Rapid virological response in hepatitis C virus genotype 1 and early ribavirin exposure. Hepatology. 2008 Aug;48(2):692-3; author reply 693-4. doi: 10.1002/hep.22409. No abstract available.
- Huang JF, Dai CY, Lin YY, Yu ML, Liu SF, Lin IL, Hsieh MY, Lee LP, Lin ZY, Chen SC, Hsieh MY, Chang WY, Chuang WL. Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections. Clin Chem Lab Med. 2008;46(4):475-80. doi: 10.1515/CCLM.2008.082.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PH-CP015
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis C Virus Infection
-
University Health Network, TorontoCompletedChronic Hepatitis C Virus InfectionCanada
-
PharmaEssentiaCompletedChronic Hepatitis C Virus InfectionKorea, Republic of, Taiwan, China
-
Gilead SciencesCompleted
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsWithdrawnChronic Hepatitis C Virus InfectionIsrael
-
Hadassah Medical OrganizationUnknownChronic Hepatitis C Virus InfectionIsrael
-
Beni-Suef UniversityCompletedChronic Hepatitis C Virus InfectionEgypt
-
Tripep ABInovio PharmaceuticalsUnknownChronic Hepatitis C Virus InfectionSweden
-
Bristol-Myers SquibbCompletedChronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus InfectionUnited States
-
Humanity and Health Research CentreBeijing 302 HospitalCompletedChronic Hepatitis C InfectionChina
-
Gilead SciencesCompletedHepatitis C Virus InfectionUnited States, Puerto Rico